共 204 条
[1]
Quigley MR(2013)The shifting landscape of metastatic breast cancer to the CNS Neurosurg Rev 36 377-382
[2]
Fukui O(2010)Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) Ann Oncol 21 942-948
[3]
Chew B(2014)Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis Breast Cancer Res Treat 147 103-112
[4]
Bhatia S(2017)Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial Ann Oncol 28 497-504
[5]
Karlovits S(2017)Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance) Ann Surg 266 667-676
[6]
Niwinska A(2012)Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype Breast Cancer Res Treat 136 153-160
[7]
Murawska M(2018)Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto. San Antonio Breast Cancer Symposium 2017 Dec 5-9 Cancer Res 78 abstract nr P1-abstract 17-01
[8]
Pogoda K(2012)Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Lancet Oncol 13 135-144
[9]
Niikura N(2014)Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto) Ann Oncol 25 2363-2372
[10]
Hayashi N(2013)Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44) Eur J Cancer 49 2284-2293